Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan L Slager

Showing results (71-80 of 277) with videos related to

Pageof 28
Sort By:
Experimental Hematology|May 7, 2022
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemiaCamilia M Soof, Tanya M Spektor, Sameer A Parikh, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Cancer Research|April 23, 2009
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphomaAnne J Novak, Susan L Slager, Zachary S Fredericksen, et al.
British Journal of Haematology|September 17, 2013
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisPatricia T Greipp, Stephanie A Smoley, David S Viswanatha, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectAlain Monnereau, Susan L Slager, Ann Maree Hughes, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
Bioinformatics (Oxford, England)|August 30, 2014
RVboost: RNA-seq variants prioritization using a boosting methodChen Wang, Jaime I Davila, Saurabh Baheti, et al.
British Journal of Haematology|October 4, 2007
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaKami Maddocks-Christianson, Susan L Slager, Clive S Zent, et al.
International Journal of Cancer|November 1, 2011
Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphomaShernan G Holtan, Helen M O'Connor, Zachary S Fredericksen, et al.
Pageof 28

Showing results (71-80 of 277) with videos related to

Sort By:
Pageof 28
Experimental Hematology|May 7, 2022
Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemiaCamilia M Soof, Tanya M Spektor, Sameer A Parikh, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Blood|July 28, 2019
Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphomaYucai Wang, Brian K Link, Thomas E Witzig, et al.
Cancer Research|April 23, 2009
Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphomaAnne J Novak, Susan L Slager, Zachary S Fredericksen, et al.
British Journal of Haematology|September 17, 2013
Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosisPatricia T Greipp, Stephanie A Smoley, David S Viswanatha, et al.
Journal of the National Cancer Institute. Monographs|September 1, 2014
Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes ProjectAlain Monnereau, Susan L Slager, Ann Maree Hughes, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
Bioinformatics (Oxford, England)|August 30, 2014
RVboost: RNA-seq variants prioritization using a boosting methodChen Wang, Jaime I Davila, Saurabh Baheti, et al.
British Journal of Haematology|October 4, 2007
Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemiaKami Maddocks-Christianson, Susan L Slager, Clive S Zent, et al.
International Journal of Cancer|November 1, 2011
Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphomaShernan G Holtan, Helen M O'Connor, Zachary S Fredericksen, et al.
Pageof 28